Business · 1 sources covering this

Dr. Lal PathLabs Gets Higher Target Price After Robust Q1, Yet ICICI Securities Downgrades Rating — Here's Why

While the company has reported strong growth for the last two quarters, sustainability of the run-rate in Q2 FY27 could indicate a trend change, adds the brokerage.

Share:WhatsApp X Reddit Facebook

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

NDTVCenter·2h ago
Dr. Lal PathLabs Gets Higher Target Price After Robust Q1, Yet ICICI Securities Downgrades Rating — Here's Why
While the company has reported strong growth for the last two quarters, sustainability of the run-rate in Q2 FY27 could indicate a trend change, adds the brokerage.
Read at NDTV →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/79ad4a0d48d666b35872befb7166e07f92c1d28f"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Dr. Lal PathLabs Gets Higher Target Price After Robust Q1, Yet ICICI Securities Downgrades Rating — Here's Why"></iframe>

Dr. Lal PathLabs Gets Higher Target Price After Robust Q1, Yet ICICI Securities Downgrades Rating — Here's Why

How 1 sources are covering this

Dr. Lal PathLabs Gets Higher Target Price After Robust Q1, Yet ICICI Securities Downgrades Rating — Here's Why

More from Business

Middle East Tensions Ease as the US and Iran Pause Hostilities

Modi Govt tables new anti-paper leak Bill amid Lok Sabha ruckus – How is it tougher than the existing Act

‘How is database secured'? SC says will see what Nandan Nilekani-led task force suggests on online NEET exam

'Will pay tribute to Mahatma Gandhi and then back to mountains': Sonam Wangchuk says as he is discharged from Medanta

Reader

Trust & legal

Across the network